title: Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction.
abstract: BACKGROUND
  In ST-segment elevation myocardial infarction, a troponin T >/=0.1 microg/L on admission indicates poorer prognosis despite early reperfusion. To evaluate the underlying reason, we studied the value of cardiac troponin T (cTnT) for prediction of outcomes, epicardial blood flow, and myocardial reperfusion after primary percutaneous intervention.
  
  
  RESULTS
  Patients (n=140) admitted within 12 hours after onset of symptoms were stratified by admission cTnT. Epicardial and myocardial reperfusion were graded by the TIMI score and by measurement of relative increases of myoglobin, cTnT, and creatine kinase (CK)-MB 60 minutes after recanalization, respectively. cTnT was positive in 64 patients (45.7%) and was associated with longer median time intervals to admission (5.5 versus 3.5 hours, P<0.001) and higher mortality rates after 30 days (12.5% versus 3.9%, P=0.06) and 9 months (14% versus 3.9%, P=0.005). cTnT independently predicted a 3.2-fold risk for incomplete epicardial reperfusion (P=0.03). In addition, cTnT >/=0.1 microg/L was associated with more severely impaired myocardial perfusion despite normal epicardial flow, as indicated by lower 60-minute ratios of myoglobin (2.6 versus 7.6, P=0.007), cTnT (6.6 versus 29.2, P<0.001), and CK-MB (3.5 versus 21.4, P=0.002) and a tendency for less resolution of ST-segment elevations (54% versus 60%, P=0.08).
  
  
  CONCLUSIONS
  cTnT predicts poorer clinical outcomes, lower rates of postprocedural TIMI 3 flow, and more severely compromised myocardial perfusion despite normal epicardial flow. Thus, a cTnT-positive patient may require more aggressive adjunctive therapy when treated by percutaneous coronary intervention. The impact of preexisting or evolving microvascular dysfunction and the effect of therapies that target myocardial perfusion require further prospective evaluation.
authors.affiliation: Medizinische Klinik II, Medizinische Universität zu Lübeck, Lübeck, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Giannitsis
authors.forename: M
authors.initials: M
authors.lastname: Müller-Bardorff
authors.forename: S
authors.initials: S
authors.lastname: Lehrke
authors.forename: U
authors.initials: U
authors.lastname: Wiegand
authors.forename: R
authors.initials: R
authors.lastname: Tölg
authors.forename: B
authors.initials: B
authors.lastname: Weidtmann
authors.forename: F
authors.initials: F
authors.lastname: Hartmann
authors.forename: G
authors.initials: G
authors.lastname: Richardt
authors.forename: H A
authors.initials: HA
authors.lastname: Katus
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D003326:Coronary Circulation; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood / Q000473:pathology / Q000628:therapy*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D009211:Myoglobin / Q000097:blood; D010343:Patient Admission; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014336:Troponin / Q000097:blood*
chemical_list: D015415:Biomarkers; D007527:Isoenzymes; D009211:Myoglobin; D014336:Troponin; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form